These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 31461674

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR, Dietrich J, Atkins KM, Oh KS, Loeffler JS, Shih HA.
    Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Observation after surgery for low grade glioma: long-term outcome in the light of the 2016 WHO classification.
    Jansen E, Hamisch C, Ruess D, Heiland DH, Goldbrunner R, Ruge MI, Schnell O, Grau SJ.
    J Neurooncol; 2019 Dec; 145(3):501-507. PubMed ID: 31621043
    [Abstract] [Full Text] [Related]

  • 6. Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas.
    Aoki K, Suzuki H, Yamamoto T, Yamamoto KN, Maeda S, Okuno Y, Ranjit M, Motomura K, Ohka F, Tanahashi K, Hirano M, Nishikawa T, Shimizu H, Kitano Y, Yamaguchi J, Yamazaki S, Nakamura H, Takahashi M, Narita Y, Nakada M, Deguchi S, Mizoguchi M, Momii Y, Muragaki Y, Abe T, Akimoto J, Wakabayashi T, Saito R, Ogawa S, Haeno H, Natsume A.
    Cancer Res; 2021 Sep 15; 81(18):4861-4873. PubMed ID: 34333454
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
    Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM.
    Neuro Oncol; 2017 Feb 01; 19(2):242-251. PubMed ID: 27571885
    [Abstract] [Full Text] [Related]

  • 8. Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
    Qiu X, Chen Y, Bao Z, Chen L, Jiang T.
    Radiother Oncol; 2022 Feb 01; 167():1-6. PubMed ID: 34902368
    [Abstract] [Full Text] [Related]

  • 9. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O, Carrato C, de Aguirre I, Queralt C, Muñoz A, Ramirez JL, Rosell R, Villà S, Diaz R, Estival A, Teixidor P, Indacochea A, Ahjal S, Vilà L, Balañá C.
    J Neurooncol; 2017 Nov 01; 135(2):273-284. PubMed ID: 28884377
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Risk Factors for Malignant Transformation of Low-Grade Glioma.
    Murphy ES, Leyrer CM, Parsons M, Suh JH, Chao ST, Yu JS, Kotecha R, Jia X, Peereboom DM, Prayson RA, Stevens GHJ, Barnett GH, Vogelbaum MA, Ahluwalia MS.
    Int J Radiat Oncol Biol Phys; 2018 Mar 15; 100(4):965-971. PubMed ID: 29485076
    [Abstract] [Full Text] [Related]

  • 12. IDH mutation is associated with higher risk of malignant transformation in low-grade glioma.
    Leu S, von Felten S, Frank S, Boulay JL, Mariani L.
    J Neurooncol; 2016 Apr 15; 127(2):363-72. PubMed ID: 26780338
    [Abstract] [Full Text] [Related]

  • 13. Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option?
    Franceschi E, Tosoni A, De Biase D, Lamberti G, Danieli D, Pizzolitto S, Zunarelli E, Visani M, Di Oto E, Mura A, Minichillo S, Scafati C, Asioli S, Paccapelo A, Bartolini S, Brandes AA.
    Oncologist; 2019 May 15; 24(5):664-670. PubMed ID: 30777895
    [Abstract] [Full Text] [Related]

  • 14. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
    Wang J, Yan L, Ai P, He Y, Guan H, Wei Z, He L, Mu X, Liu Y, Peng X.
    Neurosurg Rev; 2021 Jun 15; 44(3):1447-1455. PubMed ID: 32529528
    [Abstract] [Full Text] [Related]

  • 15. The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
    Bady P, Kurscheid S, Delorenzi M, Gorlia T, van den Bent MJ, Hoang-Xuan K, Vauléon É, Gijtenbeek A, Enting R, Thiessen B, Chinot O, Dhermain F, Brandes AA, Reijneveld JC, Marosi C, Taphoorn MJB, Wick W, von Deimling A, French P, Stupp R, Baumert BG, Hegi ME.
    Acta Neuropathol; 2018 Apr 15; 135(4):601-615. PubMed ID: 29368212
    [Abstract] [Full Text] [Related]

  • 16. Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era.
    Tom MC, Varra V, Leyrer CM, Park DY, Chao ST, Yu JS, Suh JH, Reddy CA, Balagamwala EH, Broughman JR, Kotagal KA, Vogelbaum MA, Barnett GH, Ahluwalia MS, Peereboom DM, Prayson RA, Stevens GHJ, Murphy ES.
    Int J Radiat Oncol Biol Phys; 2019 Aug 01; 104(5):1099-1105. PubMed ID: 31022510
    [Abstract] [Full Text] [Related]

  • 17. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T, Sonoda Y, Shibahara I, Saito R, Kanamori M, Kumabe T, Tominaga T.
    J Neurooncol; 2016 Sep 01; 129(3):505-514. PubMed ID: 27401154
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
    Rudà R, Pellerino A, Pace A, Carapella CM, Dealis C, Caroli M, Faedi M, Bello L, Migliore E, Marchese G, Bertero L, Cassoni P, Soffietti R.
    J Neurooncol; 2019 Oct 01; 145(1):115-123. PubMed ID: 31556015
    [Abstract] [Full Text] [Related]

  • 19. Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype.
    Patel SH, Bansal AG, Young EB, Batchala PP, Patrie JT, Lopes MB, Jain R, Fadul CE, Schiff D.
    AJNR Am J Neuroradiol; 2019 Jul 01; 40(7):1149-1155. PubMed ID: 31248860
    [Abstract] [Full Text] [Related]

  • 20. Systemic screening identifies GABRD, a subunit gene of GABAA receptor as a prognostic marker in adult IDH wild-type diffuse low-grade glioma.
    Zhang H, Zhang L, Tang Y, Wang C, Chen Y, Shu J, Zhang K.
    Biomed Pharmacother; 2019 Oct 01; 118():109215. PubMed ID: 31545245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.